Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1098 • ACR Convergence 2024
Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study
Antonio Avilés¹, Zulema Plaza², Fernando Sánchez-Alonso³, Santos Castañeda⁴, Benjamin fernandez-Gutierrez⁵, César Díaz⁶, Pilar Font⁷, Olga Martinez⁸, Emilio Giner⁹, José Miguel Senabre¹⁰, Amalia Rueda¹¹, Ana Perez¹², Gines Sanchez¹³, Carlos Gonzalez¹⁴, Javier García¹⁵, Javier Llorca¹⁶, Miguel Angel Gonzalez-Gay¹⁷ and Mariano Andres¹⁸, and CARMA project, reserch group., ¹Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, ²Fundacion Española de Reumatología, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁸Hospital Universitario de Salamanca, Zamora, Spain, ⁹Hospital Royo Villanova, Teruel, Spain, ¹⁰Hospital Marina Baixa Alicante, Alicante, Spain, ¹¹Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, ¹²Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ¹³Hospital General de Albacete, Albacete, Spain, ¹⁴Hospital Universitario Lucus Augusti; Biodiscovery HULA-USC Group, Instituto de Investigación Sanitaria de Santiago de Compostela IDIS., Lugo, Spain, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, ¹⁷University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁸Hospital General Universitario de Alicante, Alicante, Spain
Background/Purpose: The role of concurrent hyperuricemia as a cardiovascular risk factor in patients with chronic inflammatory arthritis (CIA) has yet to be studied. We aim…
Abstract Number: 1331 • ACR Convergence 2024
Does Refractory Rheumatoid Arthritis Status Matter in Modeling Patient Global Assessment Trajectories over 20 Years in a Large US Registry?
Sofia Pedro¹, Kristin Wipfler², Urbano Sbarigia³, Federico Zazzetti⁴, Anna Sheahan⁵, Patti Katz⁶ and Kaleb Michaud⁷, ¹Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Janssen, Chapel Hill, NC, ⁶UCSF, San Rafael, CA, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Refractory rheumatoid arthritis (reRA) is characterized by an inadequate response to multiple DMARDs. Many factors including environment, comorbidities, sociodemographics, and the treatment itself influence poor…
Abstract Number: 1347 • ACR Convergence 2024
Interest of DAS28-γGT in Assessing Cardiovascular Risk Activity in Rheumatoid Arthritis in Routine Practice
Manon Lesturgie-Talarek¹, Fabien Picard², sabrina hamroun³, Malika Saadi², Camille Macher⁴, Aude Deloumeau³, Karim Wahbi², jacques Blacher⁴, Yannick Allanore⁵ and Jérôme Avouac⁶, ¹Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ²Cardiology Department - Cochin Hospital, Paris, France, ³Rheumatology Department - Cochin Hospital, Paris, France, ⁴Cardiology Department, Hôtel Dieu Hospital, Paris, France, ⁵Université Paris Cité, Paris, France, ⁶Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular (CV) mortality, linked to systemic inflammation and the presence of associated CV risk factors.…
Abstract Number: 1363 • ACR Convergence 2024
Prevalence and Predictors of Orthopaedic Surgery in Rheumatoid Arthritis After 12-Years’ Follow-Up (ESPOIR Cohort)
Michael Wang¹, Baptiste Quere¹, Paul Thomas¹, Alice TISON², Dewi Guellec¹, Cecile Gaujoux-Vialat³, Jean Francis Maillefert⁴, Sandrine Jousse-Joulin⁵, Valerie Devauchelle⁶, Hoel Letissier¹ and Alain SARAUX⁷, ¹Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, ²CHU de la Cavale Blanche, Brest, France, Brest, France, ³CH Nimes, Nimes, France, ⁴CH Dijon, Dijon, France, ⁵cavale blanche hospital, brest, France, ⁶UBO, Brest, France, ⁷CHU Brest, Brest, France
Background/Purpose: In the 1990s, surgery was a frequent and early step in the management of rheumatoid arthritis. Since treat to target strategy and the advent…
Abstract Number: 1379 • ACR Convergence 2024
Association Between Body Mass Index and the Persistence of Non-TNF-Targeted Biologics in Patients with Rheumatoid Arthritis
Dong-Jin Park¹, Hyemin Jeong², Sung-Eun Choi³, Ji-Hyoun Kang² and Shin-Seok Lee⁴, ¹Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Chonnam National University Hospital, Gwangju, South Korea, ³Chonnam National University Medical School & Hospital, Gwangju, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea
Background/Purpose: Recent studies have shown the impact of obesity on achieving low disease activity (LDA) or remission in rheumatoid arthritis (RA) patients treated with TNF…
Abstract Number: 1396 • ACR Convergence 2024
Low CD47 Expression on B Cells, Induces High B Cell Phagocytosis by Macrophages and Is a Predictive Biomarker of Anti-rituximab Antibodies and Lower Response in Rheumatoid Arthritis
Samuel Bitoun¹, Bineta Ly², Audrey Paoletti², Catherine Menier Menier³, Marc Pallardy⁴, Bernard Maillere⁵ and Xavier Mariette⁶, and ABIRISK consortium, ¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ²Rheumatology departement, Université Paris Saclay, Inserm UMR 1184,Hopital Bicêtre, APHP, FHU CARE, Le Kremlin Bicêtre, France, ³1 CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, ⁴Université Paris-Saclay, INSERM, Inflammation Microbiome Immunosurveillance, Orsay, France, ⁵CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Rituximab (RTX) provides long lasting efficacy in the control of rheumatoid arthritis. Among factors associated with RTX failure are the occurrence of anti-drug antibodies…
Abstract Number: 1664 • ACR Convergence 2024
Identification of Spatial Determinants of Treatment Response in Rheumatoid Arthritis Synovia
ilya Korsunsky¹, Roopa Madhu², Kevin Wei³, Kartik Bhamidipati¹, Miles Tran¹, Sonia Presti¹, Anna Helena Jonsson⁴, Ellen Gravallese⁵, Michael Brenner⁶, Soumya Raychaudhuri¹, Jennifer Seifert⁷, Costantino Pitzalis⁸, Fan Zhang⁹, Larry Moreland¹⁰, V. Michael Holers¹⁰, Michael Clayman¹¹, Myles Lewis¹², Ce Gao¹, Michael J Zuscik¹³ and Accelerating Medicines Partnership Autoimmune and Immune-Mediated Disease¹⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁴University of Colorado School of Medicine, Aurora, CO, ⁵Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ⁶Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ⁷University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁸QMUL, Bromley Kent, United Kingdom, ⁹University of Colorado, Aurora, CO, ¹⁰University of Colorado, Denver, CO, ¹¹University of Colorado School of Medicine, Burlington, MA, ¹²Queen Mary University of London, London, United Kingdom, ¹³Department of Orthopedic Surgery, University of Colorado School of Medicine, Aurora, CO, ¹⁴Multiple Institutions, Oklahoma City
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by immune infiltration of the synovial tissue, resulting in joint damage. In RA, synovia exhibit distinct…
Abstract Number: 1746 • ACR Convergence 2024
Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Rheumatoid Arthritis
Andreas Kerschbaumer¹, Marlene Steiner², Pascale Pruckner¹, Josef Smolen³ and Daniel Aletaha⁴, ¹Medical University of Vienna, Vienna, Wien, Austria, ²Medical University Vienna, Vienna, Wien, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria
Background/Purpose: Therapeutic advances of the recent past have led to significant changes in clinical practice when treating patients with rheumatoid arthritis (RA). Since the advent…
Abstract Number: 1881 • ACR Convergence 2024
Cross-State Comparative Assessment of Burden of Rheumatoid Arthritis in the United States and It’s Trend from 1990-2021: A Benchmarking Analysis for the Global Burden of Disease Study 2022
Rafael Sanchez-Dopazo,¹, Eva Kalra², Shadi Abuhashem³, abobakr Saleh⁴, Khalid Faris⁵, Rutvik Raval⁶, Shamitha Hejmadi⁶, Lovekumar Vala⁷, Riya Dhadhal⁸ and Hardik Desai⁹, ¹Larkin Community Hospital Palm Springs Campus, Hialeah, FL, ²Trident Medical Cente, Charleston, SC, ³Alquds University, Jerusalem, West Bank, Palestine, 9458123, Gaza, Palestinian Territories, ⁴kasr alainy Medical School - Cairo University,Egypt/ 11956, Cairo, Egypt, ⁵Studied in Al-Quds university, Palestine, Gaza, Palestinian Territories, ⁶B.J. Medical College, Ahmedabad, India, ⁷Department of Internal Medicine, Shantabaa Medical College and General Hospital, Amreli, Gujarat, India, 365601, Amreli, Gujarat, India, ⁸SMIMER Hospital & Medical College, Surat, Gujarat, India, ⁹Gujarat Adani Institute of Medical Sciences, Bhuj, India
Background/Purpose: The burden of Rheumatoid Arthritis (RA) in the United States is considerable, both in terms of its prevalence and the economic costs it incurs.…
Abstract Number: 1964 • ACR Convergence 2024
Comparison of Knee Minimum Joint Space Width Measurements Using Deep Learning in Patients with Rheumatoid Arthritis and Osteoarthritis Undergoing Total Knee Arthroplasty
Kellen Mulford¹, Elizabeth Kaji¹, Austin Grove¹, Ronnie Sebro², Cody Wyles¹, John Davis¹ and Cynthia Crowson¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Jacksonville, FL
Background/Purpose: While large joint damage is a hallmark of both Osteoarthritis (OA) and Rheumatoid Arthritis (RA), the mechanisms of degradation are substantially different. Minimum joint…
Abstract Number: 2209 • ACR Convergence 2024
Impact of Common Infections on Medication Interruptions, Quality of Life, and Disease Flares in Patients with Rheumatoid Arthritis
Michael George¹, Kelly Gavigan², Shilpa Venkatachalam³, David Curtis², Laura Stradford⁴, William Benjamin Nowell⁵, Joshua Baker¹, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Regeneron, New York, NY, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Serious infections are a major cause of morbidity and mortality in patients with RA, but less is known about more common, non-serious infections. We…
Abstract Number: 2227 • ACR Convergence 2024
Worrisome Mortality Trends over 20 Years Among Patients with Underlying Ischemic Heart Disease and Rheumatoid Arthritis
Yukthi Mudiam¹ and Shreyas Singireddy², ¹Apollo Institute of Medical Sciences and Research, Richmond, TX, ²Department of Cardiology, University of Illinois College of Medicine, Peoria, IL
Background/Purpose: Ischemic heart disease (IHD) is one of the leading causes of death in the United States. Rheumatoid arthritis (RA), a chronic inflammatory condition affecting…
Abstract Number: 2243 • ACR Convergence 2024
A Cross-sectional Study of the Association Between Anxiety State and Various Factors in Patients with Rheumatoid Arthritis
Yusuke Miwa¹, Yuko Miwa² and Michio Hosaka³, ¹Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Tokyo, Japan, ²Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Setagaya-ku, Tokyo, Japan, ³Department of psychosomatic medicine, Katsuyama Clinic, Kawaguchiko, Yamanashi, Japan
Background/Purpose: Although the complication of anxiety in rheumatoid arthritis (RA) patients is reported to be 1.2 times higher than in healthy controls and weakly correlated…
Abstract Number: 2263 • ACR Convergence 2024
The Potential Use of Circulating Extracellular Vesicles for Improved Diagnosis and Therapy in Rheumatic Inflammatory/autoimmune Diseases: Proof of Concept Studies
Gilad Halpert¹, Ori Moskovitch², Linoy Israel², Eri Govrin², Boris Gilburd², Ori Segal², Adi Anaki³, Tal Caller², Daniel Yechiali², Shlomo Segev², Omer Gendelman⁴, Abdulla Watad⁵, Ruty Mehrian-Shai², Rachella Popovtzer³ and Howard Amital⁶, ¹CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, ²Sheba Medical Center, Ramat-Gan, Israel, ³Bar Ilan University, Ramat-Gan, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Tel Hashomer Medical Center, Ramat Gan, Israel, ⁶Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel
Background/Purpose: Many patients with rheumatic conditions do not completely respond or are refractory to biological therapy. Therefore, there are unmet medical needs in the treatment…
Abstract Number: 2281 • ACR Convergence 2024
Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab
Monica Luque¹, Kristina Zhelyazkova¹, Laxmikant Vashishta², Masna Rai³, Abid Sattar⁴, Richard Bucknall⁴, Steffen Leutz³ and FAUSTO BERTI¹, ¹Alvotech, Zürich, Switzerland, ²Alvotech, Bangalore, India, ³Alvotech, Jülich, Germany, ⁴Alvotech, London, United Kingdom
Background/Purpose: Golimumab is a safe and effective treatment for RA. Biosimilars to the reference product (RP) may make treatment more accessible. We assessed comparable efficacy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].